Cerenovus, a neurovascular firm that forms part of The Johnson & Johnson Medical Devices Companies, will showcase its latest innovations in stroke care at the Society of NeuroInterventional Surgery annual meeting (SNIS; July 26–29 2021, Colorado Springs, USA and virtual). The company will also announce new data during poster sessions, and feature innovations across its ischaemic and haemorrhagic portfolios that reflect its continued commitment to changing the trajectory of stroke, according to a press release.
“Stroke can be a devastating event for patients and their loved ones, and survival depends on physicians treating their patients effectively and efficiently,” said Mark Dickinson, worldwide president, Cerenovus. “We are looking forward to sharing our latest research and innovations with colleagues and industry leaders that build on our commitment to develop differentiated solutions based on physicians’ real-world stroke care experiences.”
Cerenovus will host a variety of interactive experiences at its booth, Booth 509, with hands-on demonstrations and education featuring technologies from its ischaemic and haemorrhagic portfolios, including Cerenovus Stroke Solutions, which includes a suite of three devices, and the TRUFILL n-BCA liquid embolic system.
Cerenovus is also supporting four scientific poster sessions at SNIS 2021. One oral poster viewing session titled “Multimodal endovascular treatment of wide-necked aneurysms: safety and occlusion outcomes from the STERLING registry” will be held on 28 July. The study findings will be presented by study co-primary investigator Reade De Leacy (assistant professor of Neurosurgery and Radiology, Mount Sinai Health System, New York, USA), on behalf of STERLING investigators.
Additional poster sessions will be available for viewing, including:
- Impact of COVID-19-related restrictions on clinical trials—insights on the STERLING registry by lead author Brian Jankowitz (director of Cerebrovascular and Neuroendovascular Surgery and associate professor of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, USA), on behalf of STERLING investigators.
- A prospective, multicentre, randomised controlled pivotal study to evaluate the safety and effectiveness of TRUFILL n-BCA embolisation of the middle meningeal artery for the treatment of subdural haematoma by lead author and study co-primary investigator Christopher Kellner (cerebrovascular neurosurgeon, Mount Sinai Health, New York, USA) on behalf of the MEMBRANE steering committee.
- The EMBOTRAP stent retriever for treatment of acute ischaemic stroke: Impact of hospital procedural volume on real-world outcomes, led by Shelly Ikeme (global head of Health Economics and Market Access [HEMA] for Acclarent, Mentor and Cerenovus Companies, Philadelphia, USA).
In addition, Cerenovus will be sponsoring several events that bring together members of the neurointerventional community to discuss the latest advances in stroke care, the release adds.